Paper Details

  1. Home
  2. Paper Details

Adverse Events and Androgen Receptor Signaling Inhibitors in the Treatment of Prostate Cancer: A Systematic Review and Multivariate Network Meta-analysis.

Author: CaoBrent, KimMelissa, MoreiraDaniel M, ReizineNatalie M

Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

A systematic review of 14 randomized controlled trials compared the adverse event profiles of four androgen receptor signaling inhibitor (ARSi) drugs (abiraterone, apalutamide, darolutamide, and enzalutamide) for prostate cancer. The review found that the side-effect profiles were similar except for a higher risk of hypertension and headache with enzalutamide. Close blood-pressure monitoring for enzalutamide is recommended.
Paper Details　
Original Abstract of the Article :
CONTEXT: Androgen receptor signaling inhibitor (ARSi) agents are emerging as standard treatments for prostate cancer across the disease spectrum, but much remains unknown regarding how their side-effect profiles compare. OBJECTIVE: To systematically evaluate the literature regarding adverse events ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.euo.2023.01.001

データ提供：米国国立医学図書館（NLM）

The Desert of Prostate Cancer Treatment: A Comparison of Androgen Receptor Signaling Inhibitors

Prostate cancer is a common and often challenging disease. This research explores the side-effect profiles of androgen receptor signaling inhibitors (ARSis), a class of drugs used to treat prostate cancer. The researchers conducted a systematic review and network meta-analysis of clinical trials, comparing the adverse events (AEs) associated with different ARSi drugs. Their findings provide valuable insights into the relative toxicity of these medications and highlight the importance of [specific discovery] in managing patient care.

Navigating the Desert of Side Effects

The study found that [specific numerical results], indicating that while the overall side-effect profiles of ARSis are similar, there are some differences in the frequency and severity of certain AEs. It's like navigating a desert with different pathways, each with its own challenges and rewards. This research helps clinicians to make informed decisions about which ARSi drug is best suited for their patients, considering individual risk factors and potential side effects.

The Desert of Prostate Cancer Treatment: A Journey of Awareness

This research emphasizes the need for careful monitoring and management of patients taking ARSi drugs. It's a reminder that even in the vast desert of cancer treatment, there are opportunities for improvement and optimization. This study encourages further research into the long-term effects of ARSi drugs and the development of personalized strategies to minimize side effects and improve patient outcomes.

Dr. Camel's Conclusion

This research provides a comprehensive overview of the side-effect profiles of ARSi drugs used to treat prostate cancer. It's a reminder that the desert of cancer treatment is complex and requires a thoughtful approach to manage patient care. By understanding the relative toxicity of different ARSi drugs and implementing appropriate monitoring strategies, we can help to ensure that patients receive safe and effective treatment.

Date :
  1. Date Completed 2023-06-19
  2. Date Revised 2023-11-16
Further Info :

Pubmed ID

36682938

DOI: Digital Object Identifier

10.1016/j.euo.2023.01.001

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.